Diffuse in-stent restenosis (ISR) in long-stented segment in the superficial femoral artery (SFA)

angiogram

Challenge

  • 59-year-old female with right calf claudication
  • Relevant patient history:
    • Diabetes, hypertension, hyperlipidemia, former smoker
    • Previous bare-metal stenting of the right SFA for diffuse disease
    • Recurrent severe right calf claudication six months later

Image: Diffuse SFA in-stent restenosis in long-stented segment in the SFA
Images courtesy of Robert Minor, MD. Used with permission.

angiogram

Procedure

  • Atherectomy with distal embolic protection was used to debulk the lesion
  • Stent graft diameters (inflow and outflow) were selected based on the measured diameter of the healthy vessel proximal and distal to the bare-metal stents
  • Stent grafts extended a minimum of 1 cm beyond bare-metal stents

Images (from left to right): Atherectomy device with distal embolic protection; Result after atherectomy; Placement of two 6 mm and one 7 mm stent grafts
Images courtesy of Robert Minor, MD. Used with permission.

angiogram

Result

  • No distal embolization
  • All GORE® VIABAHN® Devices are patent through follow-up at nine months

Image: Completion angiogram after placement of GORE® VIABAHN® Devices for ISR in the SFA
Images courtesy of Robert Minor, MD. Used with permission.

Case takeaways

  • The use of the GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface*,† provides an excellent treatment option for ISR in the SFA, particularly when it involves a long stented segment
  • Atherectomy can be used as an adjunct to provide debulking of the restenotic tissue, and optimize stent graft expansion

* As used by Gore, PROPATEN Bioactive Surface refers to Gore's proprietary CBAS Heparin Surface.

† Also referred to as the GORE® VIABAHN® Endoprosthesis with Heparin Bioactive Surface in some regions.

The outcomes and observations reported are based on individual case experience and the patients treated. The steps described here may not be complete, and are not intended to be a replacement for the Instructions for Use or the education, training and professional judgment of Healthcare Providers. Healthcare Providers remain solely responsible for making decisions about patient care and the use of medical technologies. 

Refer to Instructions for Use at eifu.goremedical.com for complete description of all indications, warnings, precautions and contraindications for the markets where this product is available.  

Visit our clinical uses page

Residents of some states have the right to opt-out of the “sharing” or “selling” of their personal information. Gore does not "sell" the personal information of website users. Gore may "share" the personal information of website users, as standard advertising practice meant to offer you a more personalized service.

If you want to opt-out from Gore “sharing” your personal information, click on Opt-Out of Sharing to turn off the targeting cookies that we share with our advertising partners in order to provide you with personalized information. Disabling sharing will stop the use of cookies to targeted advertising but you may still see generic Gore ads.

Please note that your exercising of the rights outlined will have no adverse effect on the price and quality of our goods or services.

Opt-Out of Sharing

You Have Successfully Opted Out of the Sharing of Your Personal Information

Please note that if you clear your cookies and then use another device or browser, etc. your opt-out status is not transferred to the new device or browser.